John D. Halpern Divests Entire Stake in Eterna Therapeutics

TL;DR

**Halpern sold all his Eterna Therapeutics shares; big investor out!**

AI Summary

John D. Halpern, an individual investor, has filed an amendment (SC 13G/A) on January 31, 2024, indicating a significant change in his beneficial ownership of Eterna Therapeutics Inc. (NASDAQ: ERNA) common stock as of December 31, 2023. Halpern now reports having 0 shares with sole voting power and 0 shares with shared voting power, a decrease from his previous holdings. This matters to investors because it signals a complete divestment of his stake, potentially indicating a loss of confidence in the company's future prospects by a notable individual investor.

Why It Matters

This filing shows a significant individual investor, John D. Halpern, has sold all his shares in Eterna Therapeutics, which could be interpreted negatively by the market.

Risk Assessment

Risk Level: medium — The complete divestment by a reporting person could signal underlying concerns about the company's performance or future outlook, increasing investment risk.

Analyst Insight

A smart investor would consider this complete divestment by John D. Halpern as a potential red flag and conduct further due diligence into Eterna Therapeutics' recent performance and future outlook before making investment decisions.

Key Numbers

• 0 — Sole Voting Power Shares (John D. Halpern's current sole voting power shares in Eterna Therapeutics Inc. as of December 31, 2023.)
• 0 — Shared Voting Power Shares (John D. Halpern's current shared voting power shares in Eterna Therapeutics Inc. as of December 31, 2023.)

Key Players & Entities

• John D. Halpern (person) — reporting person and individual investor
• Eterna Therapeutics Inc. (company) — the subject company whose securities are being reported
• 0 (dollar_amount) — shares with sole voting power
• 0 (dollar_amount) — shares with shared voting power
• December 31, 2023 (date) — date of event requiring the filing
• January 31, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Eterna Therapeutics' stock price may experience downward pressure due to the complete divestment by a notable individual investor. (Eterna Therapeutics Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.005 — me of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securiti
• $3.28 — of Common Stock at an exercise price of $3.28 per share. On July 14, 2023, the Trust
• $1,000,000 — ate placement (the July 2023 PIPE): (i) $1,000,000 in principal amount of the Issuers 6.0%
• $2.61 — e Common Stock, at an exercise price of $2.61 per share (the July 2023 Warrants). The
• $2.86 — f Common Stock at a conversion price of $2.86 per share, subject to customary adjustm
• $1.43 — f Common Stock, at an exercise price of $1.43 per share (the December 2023 Warrants,
• $1.9194 — f Common Stock at a conversion price of $1.9194 per share, subject to customary adjustm

Filing Documents

• d629436dsc13ga.htm (SC 13G/A) — 63KB
• d629436dex99a.htm (EX-99.A) — 3KB
• 0001193125-24-020217.txt ( ) — 68KB

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 31, 2024 By: /s/ John D. Halpern John D. Halpern By: /s/ Katherine H. Halpern Katherine H. Halpern

View Full Filing

View this SC 13G/A filing on SEC EDGAR